NGS Oncology Market Growth Outlook Through 2030 Highlighting Market Expansion Trends

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The NGS Oncology Market In 2026, And How Will Its Value Evolve By 2030?

The ngs oncology market has experienced significant expansion recently. This market is projected to expand from $19.33 billion in 2025 to $21.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.4%. Factors contributing to this historical growth include declining sequencing costs, rising global cancer prevalence, increased oncology research funding, early adoption of targeted therapies, and the growth of genomic research initiatives.

The ngs oncology market is projected for substantial expansion in the coming years. It is anticipated to reach $32.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. This increase during the projected period stems from factors such as the expansion of precision oncology programs, rising demand for personalized cancer treatments, a surge in approvals for ngs-based diagnostics, progress in bioinformatics analytics, and the incorporation of ngs into standard clinical guidelines. Key trends expected over the forecast horizon encompass broader comprehensive tumor profiling, greater uptake of liquid biopsy NGS, enhanced clinical applicability of multi-gene panels, the incorporation of NGS into everyday oncology diagnostics, and an increasing need for quicker sequencing workflows.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

What Significant Factors Are Influencing The NGS Oncology Market Expansion?

The increasing incidence of cancer is anticipated to drive the expansion of the NGS oncology market in the future. Cancer is characterized by the uncontrolled proliferation of anomalous cells, which can spread to other bodily regions and disrupt regular physiological processes. This increase in cancer cases is largely attributed to an aging populace, overall population expansion, and greater exposure to risk factors such as tobacco use, alcohol consumption, obesity, and air pollution. NGS oncology contributes to public health and enhances patient care through facilitating early discovery, accurate diagnosis, and tailored treatment strategies via comprehensive genetic profiling of tumors. For example, data released in January 2024 by the American Cancer Society, a US-based non-profit organization, indicates that the United States is forecast to record 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, a rise from 1,958,310 cases and 609,820 deaths in 2023. Consequently, the growing occurrence of cancer is a key factor propelling the expansion of the NGS oncology market.

Which Segment Classifications Are Used In The NGS Oncology Market Segment Analysis?

The ngs oncology market covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing, Genomics, Transcriptomics, Epigenomics

2) By Offering: Platform, Kits, Services

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Genetic Screening, Hereditary Genetic Testing, Hematological Malignancies, Solid Tumors, Other Applications

5) By End User: Hospitals And Clinics, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES), Amplicon-Based Sequencing, Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS), Structural Variant Detection, Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing, Single-Cell Transcriptomics, Non-Coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing, Chromatin Immunoprecipitation Sequencing, Histone Modification Analysis

What Trends Are Affecting The Direction Of The NGS Oncology Market?

Leading firms within the NGS oncology market are concentrating on creating advanced solutions, including liquid biopsy research assays, to facilitate non-invasive, real-time cancer identification and tracking by analyzing circulating tumor DNA. This type of diagnostic test examines biological fluids, like blood, to identify genetic alterations or other molecular indicators linked to cancer, thereby supporting non-invasive cancer detection and monitoring. For example, in August 2024, Illumina Inc., a US-based biotechnology company focused on next-generation sequencing (NGS) technology, broadened its oncology offerings for users of its NovaSeq X Series. The company now provides the recently validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the upgraded TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These improved assays empower laboratories to expand their oncology research capacities for both tissue and liquid biopsy samples, offering better sequencing efficiency, shorter run durations, and the novel capability to process greater sample volumes on the NovaSeq X Series.

Which Firms Are Contributing To The NGS Oncology Market Ecosystem?

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Get The Full NGS Oncology Market Report:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Which Region Holds The Highest Market Share In The NGS Oncology Market?

North America was the largest region in the NGS oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized NGS Oncology Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Browse Through More Reports Similar to the Global NGS Oncology Market 2026, By The Business Research Company

Ngs Based Rna Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report

Prenatal Dna Sequencing Market Report

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Next Generation Firewall Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-firewall-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795